Strategic Milestone Achievement and Increased Financial Discipline Underscore Year of Corporate Transformation Completed ...

Analysts estimate that CureVac will report an earnings per share (EPS) of $-0.09. Investors in CureVac are eagerly awaiting ...

The US Food and Drug Administration (FDA) has granted clearance to CureVac's investigational new drug application (IND) for ...

CureVac (CVAC) announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for a Phase 1 clinical ...

The live webcast link can be accessed via the newsroom section of the CureVac website at https://www.curevac.com/en/newsroom/events/ Corresponding presentation slides ...

As we previously discussed, beginning in 2022, a series of patent infringement lawsuits were filed against Moderna and ...

Moderna's mRNA technology gained rapid validation as sales of its covid vaccine soared in 2021 and 2022, but we think the firm has yet to secure a narrow economic moat around its business, largely due ...

Curevac NV announced that the FDA has cleared its IND application for a phase I clinical study of CVHNLC in patients with ...

GSK has upgraded its longstanding alliance with CureVac on mRNA-based vaccines for respiratory infections, paying €400 million ($429 million) upfront for global rights to its influenza and COVID ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.